|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1993-3-24
|
|
pubmed:abstractText |
Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1 alpha could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carboplatin in 43 patients with advanced neoplasms.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0028-4793
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
18
|
|
pubmed:volume |
328
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
756-61
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8437596-Adult,
pubmed-meshheading:8437596-Aged,
pubmed-meshheading:8437596-Carboplatin,
pubmed-meshheading:8437596-Drug Therapy, Combination,
pubmed-meshheading:8437596-Female,
pubmed-meshheading:8437596-Humans,
pubmed-meshheading:8437596-Interleukin-1,
pubmed-meshheading:8437596-Male,
pubmed-meshheading:8437596-Middle Aged,
pubmed-meshheading:8437596-Neoplasms,
pubmed-meshheading:8437596-Pilot Projects,
pubmed-meshheading:8437596-Platelet Count,
pubmed-meshheading:8437596-Thrombocytopenia,
pubmed-meshheading:8437596-Time Factors
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
|
|
pubmed:affiliation |
Biological Response Modifiers Program, Frederick Cancer Research and Development Center, National Cancer Institute, Md.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
